U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported)    September 20, 2005    

VION PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)

Delaware (State or Other Jurisdiction of Incorporation)				000-26534 (Commission File Number)				13-3671221 (IRS Employer Identification No.)
4 Science Park, New Haven, CT (Address of Principal Executive Offices)								06511 (Zip Code)

Registrant's telephone number, including area code:       (203) 498-4210    

                                                Not Applicable                                                
(Former Name or Former Address, if Changed Since Last Report)

Item 8.01    Other Events

On September 20, 2005, Vion Pharmaceuticals, Inc. issued a press release announcing that it initiated a Phase II clinical trial of its anticancer agent Cloretazine^® in small cell lung cancer. A copy of Vion's press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.

Item 9.01    Financial Statements and Exhibits.

(c)    Exhibits.

        Exhibit 99.1    Press release dated September 20, 2005.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VION PHARMACEUTICALS, INC.

Date: September 22, 2005	By:          /s/ Howard B. Johnson                 Name:    Howard B. Johnson Title:       President and Chief Financial Officer

EXHIBIT INDEX

99.1      Press release dated September 20, 2005.